Rollover Study for Crizanlizumab in Sickle Cell Disease
This study offers continued access to crizanlizumab for patients with sickle cell disease (SCD) who have already participated in a Novartis-sponsored crizanlizumab study and are benefiting from the treatment. Crizanlizumab is given as an intravenous (into the vein) infusion. This study is for people aged 6 months to 100 years. The main goal of this study is to allow patients to keep receiving crizanlizumab. There are no specific biomarkers (biological signs) or mechanisms (how the drug works) detected for this study. The current status of this study is unclear.
- Study design
- This is a multi-center, multi-national rollover study with a planned enrollment of 130 participants. It is an interventional study, meaning participants will receive a specific treatment.
- What's involved
- You would continue to receive crizanlizumab at the same dose and schedule as in your previous study. There is no screening period, and treatment starts soon after you provide consent.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will have a safety follow-up visit 105 days after your last treatment, unless you continue receiving crizanlizumab through other means.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
At a glance
Conditions
Where it's being run
31 sites across 23 statesStudy leadership
- Novartis Pharmaceuticals · STUDY_DIRECTOR · Novartis Pharmaceuticals
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Not Applicable as this protocol is to provide an option for continued access to crizanlizumab for patients with Sickle Cell Disease who have completed a prior Novartis-sponsored Crizanlizumab studyNot Applicable - Study Completion
Protocol to provide an option for continued access to crizanlizumab for patients with Sickle Cell Disease who have completed a prior Novartis-sponsored Crizanlizumab study, benefited from the treatment and do not have access to reimbursed, commercially available crizanlizumab.